Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.
about
Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?Empagliflozin/linagliptin single-tablet combination: first-in-class treatment optionFixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An OverviewPharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Stimulatory Effect of Balanced Deep-Sea Water Containing Chitosan Oligosaccharides on Glucose Uptake in C2C12 Myotubes.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.The power of two: an update on fixed-dose combinations for type 2 diabetes.Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.Pharmacotherapy of 'treatment resistant' type 2 diabetes.Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach.Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.Patient-centered drug delivery and its potential applications for unmet medical needs.
P2860
Q34201551-9DDC9029-463E-4372-8A5C-C4660C5C0D49Q37077196-FC99E707-8C44-4FE3-97AB-D207EC944570Q37308941-4F912951-B5A8-46AF-ACBF-A8EB7A2C9080Q37562484-CA4D46D3-0B9F-40F2-84E5-A3E146D67458Q38455771-D5066F67-F00E-4769-9D15-60131374778DQ38577303-38289006-E67F-44D2-B27B-3DFEBF417342Q38599975-04599FBF-E2DD-4537-B1D6-A80EF70763F2Q38645792-9CF0F760-5B63-4B05-8468-FA2E84E09039Q38769086-FA3FCE07-E277-443F-99A4-409CCF521F3DQ38845574-F864603F-07D6-4A3C-B148-9C6A79B99AF9Q38920983-FE62C6F4-D1A5-4168-9C32-6BCE92113609Q38972958-60535CDB-B5E7-4B6F-B5A8-19F13CB64AE0Q39170345-32577422-939A-417C-B53C-2C4EC8829E67Q47293312-19AF8283-B9EB-47FB-B139-1EF2DC89B181Q48015498-587ABFC3-1E70-4A39-B9FA-F1A221F8E163Q48040104-CA42E4CB-6243-4CBC-A618-657EC041F84DQ48140061-AD441EA1-DCBA-48D9-821C-EB210CAB0CB2Q51072174-B110F266-DC2B-4FD3-996A-2C1EFD605120Q51285159-E6389295-E073-4D3A-8F0B-18099959F85FQ53099408-CF378A7E-F0A9-4148-B7D7-00DCC02BFCF2
P2860
Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.
@en
type
label
Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.
@en
prefLabel
Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.
@en
P2860
P356
P1476
Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.
@en
P2093
D S H Bell
P2860
P304
P356
10.1111/DOM.12015
P577
2012-10-25T00:00:00Z